darodipine

Darodipine (PY 108-068) is a second-generation dihydropyridine calcium channel blocker developed by Sandoz (now Novartis). It functions as a potent antagonist of L-type voltage-gated calcium channels, which leads to the relaxation of vascular smooth muscle and subsequent vasodilation. Historically, darodipine was investigated for cardiovascular indications such as hypertension and angina pectoris. Additionally, clinical research explored its potential in respiratory medicine, specifically for the attenuation of exercise-induced asthma, where it demonstrated the ability to provide significant protection against bronchoconstriction following physical exertion. Despite showing efficacy in Phase 2 trials for asthma and cardiovascular conditions, its development was largely discontinued in favor of other dihydropyridine agents like isradipine.

Other names

darodipine